Table 1 Characteristics of the patients included in this study
‘Healthy’ (n = 6) | Metabolic syndrome (n = 12) | Diagnosed T2D (n = 10) | |
|---|---|---|---|
Gender split (male: female) | 0:6 | 3:8 | 2:8 |
Age (years) | 44.0 ± 4.7 | 44.5 ± 3.3 | 45.5 ± 2.7 |
BMI (kg.m -2 ) | 44.0 ± 4.7 | 46.3 ± 1.7 | 44.8 ± 1.5 |
Insulin (mU.L -1 ) | 12.2 ± 3.1 | 14.0 ± 2.3 | 15.9 ± 1.9 |
Glucose (mmol.L -1 ) | 5.0 ± 0.2~ | 5.1 ± 0.2* | 8.7 ± 1.4~* |
HbA1c (%) | 5.8 ± 0.1† | 5.8 ± 0.3# | 7.9 ± 0.7†# |
HOMA2-%S | 85.8 ± 26.2 | 71.4 ± 14.2 | 50.4 ± 6.8 |
MAP (mmHg) | 96.1 ± 4.8 | 96.3 ± 4.3 | 104.8 ± 3.6 |
Dyslipidaemia medication | 1 (statin) | 1 (statin) | 2 (statin) |
Hyperglycaemia medication | 0 | 0 | 5 (metformin) |
Hypertension medication | 3 (1: ACE inhibitor; 2: ACE inhibitor + thiazide diuretic) | 3 (1: ACE inhibitor; 1: ACE inhibitor + β1 antagonist; 1: ACE inhibitor + thiazide diuretic) | 3 (2: ACE inhibitor; 1: thiazide diuretic) |